Dexamethasone sodium phosphate is under clinical development by EryDel and currently in Phase I for Duchenne Muscular Dystrophy. According to GlobalData, Phase I drugs for Duchenne Muscular Dystrophy have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dexamethasone sodium phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dexamethasone sodium phosphate overview

Dexamethasone sodium phosphate is under development for the treatment of ataxia telangiectasia, non ambulatory ataxia telangiectasia and Duchenne muscular dystrophy (DMD).. The drug candidate is administered as an intravenous infusion. It targets glucocorticoid receptor. The drug candidate is based on intra-erythrocytic technology by encapsulating dexamethasone sodium phosphate into human erythrocytes. It was also under development for the treatment of the Crohn's disease, cystic fibrosis, ulcerative colitis, chronic obstructive pulmonary disease, other chronic inflammatory diseases.

EryDel overview

EryDel operates as a biotechnology company specialized in the development of drugs and diagnostics delivered through human red blood cells using its proprietary drug delivery technology. The company offers Red Cell Loader (RCL), a proprietary non-invasive electromechanical device that automates the EryDex System (EDS) process enabling encapsulation of drugs with the use of disposable medical device (EryKit_01). Its pipeline product includes EryDex System (EDS) composed of device components including multi-use Red Cell Loader (RCL), the EryKit_01, and process solutions used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes, creating the EDS end product (EDS-EP) infused once per month to treat Ataxia Telangiectasia patients. EryDel is headquartered in Milan, Lombardia, Italy.

For a complete picture of Dexamethasone sodium phosphate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.